Clinical study on balofloxacin in respiratory tract infections
スポンサーリンク
概要
- 論文の詳細を見る
Balofloxacin, a new fluoroquinolone, was administered to nine patients with respiratory tract infections at doses of 100-400 mg, once or twice a day for 3-14 days. The clinical efficacy was good in 7, fair in 1 and poor in 1 case. Two causative gram-negative bacteria that were isolated, <I>Moraxella catarrhalis</I> and <I>Haemophilus parainfluenzae</I>, were completely eliminated after the treatment.<BR>Adverse reactions were noted in 3 patients with epigastralgia, vesicle and diarrhea. No abnormal change in laboratory findings were observed.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.